Their study identified the persistent and selective expression of CD93 within a lin−CD34+CD38− CD90+ CML LSC subpopulation, which showed higher proliferative potential and could persist TKI treament [99] (Fig. 6). This evidence concerns the gene CD93 and chronic myelogenous leukemia, BCR-ABL1 positive.